Effect of Actonel on Periodontal Health of Postmenopausal Women

Phase 4

Withdrawn

• Conditions: Periodontal Disease
• Interventions: Drug: Risedronate

• Registration Number: NCT00594334
• Lead Sponsor: University Hospitals Cleveland Medical Center

Brief Summary

Hypothesis: Women who use Actonel (risedronate) for osteopenia will show beneficial periodontal effects.

Detailed Description

Women who use Actonel for osteopenia will show beneficial attachment loss, alveolar bone height and morphology as compared to those who do not when oral hygiene is corrected for.

Study Timeline

• Study Start: 2008-01
• Study First Submitted: 2008-01-03
• Study First Submitted QC: 2008-01-14
• Study First Posted: 2008-01-15
• Primary Completion: 2010-01
• Study Completion: 2011-01
• Status Verified: 2022-07
• Last Update Submitted: 2022-07-14
• Last Update Posted: 2022-07-19

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

• Osteopenia
• Postmenopausal

Exclusion Criteria

• Male
• Diabetes

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
E, I	Risedronate	-

Primary Outcome Measures

Name	Time	Method
Periodontal alveolar bone changes	one year

Secondary Outcome Measures

Name	Time	Method
Periodontal attachment levels	one year

Trial Locations

Locations (1)

Uhcmc; 🇺🇸 Cleveland, Ohio, United States